As of 2024-12-13, the Intrinsic Value of Sigilon Therapeutics, Inc. (SGTX) is (454.60) USD. This SGTX valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 22.47 USD, the upside of Sigilon Therapeutics, Inc. is -2,123.20%.
The range of the Intrinsic Value is (1,104.31) - (291.11) USD
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (1,104.31) - (291.11) | (454.60) | -2123.2% |
| DCF (Growth 10y) | (367.33) - (1,315.40) | (559.12) | -2588.3% |
| DCF (EBITDA 5y) | (294.74) - (361.41) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (371.87) - (482.14) | (1,234.50) | -123450.0% |
| Fair Value | -73.73 - -73.73 | -73.73 | -428.14% |
| P/E | (166.93) - (281.95) | (267.65) | -1291.1% |
| EV/EBITDA | (203.30) - (224.87) | (209.52) | -1032.5% |
| EPV | (189.33) - (254.13) | (221.73) | -1086.8% |
| DDM - Stable | (170.20) - (752.41) | (461.31) | -2153.0% |
| DDM - Multi | (208.56) - (724.46) | (324.81) | -1545.5% |
| Market Cap (mil) | 56.50 |
| Beta | 4.65 |
| Outstanding shares (mil) | 2.51 |
| Enterprise Value (mil) | 32.33 |
| Market risk premium | 4.60% |
| Cost of Equity | 7.91% |
| Cost of Debt | 7.99% |
| WACC | 7.40% |